Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06366490 · ClinicalTrials.gov registry record · Phase 1

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

A Phase 1 study of Ovarian Cancer and Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer, sponsored by PhotonPharma.

Recruiting
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06366490: Recruiting Phase 1 study of Ovarian Cancer and Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer, sponsored by PhotonPharma.

NCT06366490 is a Phase 1 study of Ovarian Cancer and Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer that is actively recruiting participants, run by PhotonPharma. The registered enrollment target is 8 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06366490, a Phase 1 study of Ovarian Cancer and Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer, is actively recruiting participants, sponsored by PhotonPharma.

RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer

Primary Outcome

Percent success rate to manufacture Innocell from autologous malignant tissue for patient administration

Conditions Studied

Ovarian Cancer Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer

Interventions

  • BIOLOGICAL Innocell Autologous Cellular Immunotherapy

Study Locations (1)

California

  • City of Hope - Duarte

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2026-01
Est. Completion 2026-12
Phase Phase 1
PhotonPharma

1 total trials

What NCT06366490 shows while recruiting

NCT06366490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Innocell Autologous Cellular Immunotherapy is the first listed.

NCT06366490 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06366490 about?

NCT06366490 is a clinical study titled "Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer". Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer

What is the current status of trial NCT06366490?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-01. Estimated completion is 2026-12.

What conditions does trial NCT06366490 study?

This clinical trial studies the following conditions: Ovarian Cancer, Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer.

What interventions are being tested in trial NCT06366490?

The interventions under investigation include: Innocell Autologous Cellular Immunotherapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT06366490?

This trial is sponsored by PhotonPharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06366490 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06366490's enrollment target sits among peer trials

8 315th of 322 higher than 8 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT06366490

Source: ClinicalTrials.gov NCT06366490, the US trial registry maintained by the National Library of Medicine. NCT06366490 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.